November 03, 2026

The National Stock Exchange of India Ltd
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051

BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Symbol: RELIGARE

Scrip Code: 532915

Dear Sir / Madam,

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations ("SEBI LODR"), 2015

This is in reference to our earlier announcement dated November 13, 2025, in relation to appointment of below individuals to the Board of the Company as Additional Directors (to be designated as Non - Executive and Non - Independent Director), subject to receipt of prior approval from the Reserve Bank of India (**RBI**):

1. Dr. Anand Chand Burman
2. Mr. Aditya Chand Burman
3. Mr. Mohit Burman
4. Mr. Jimeet Vipul Modi

In this regard, we would like to inform that Company is in receipt of a letter from RBI vide reference no. DEL.DOR.NBFCML.No.S981/24-05-011/2026-2027 dated November 03, 2026 granting approval to the aforesaid appointments to the Board of the Company as Directors, for a period not exceeding five years from the date of their appointment.

The aforesaid appointments shall be effective from today i.e. **November 03, 2026**.

Dr. Anand Chand Burman, Mr. Aditya Chand Burman, Mr. Mohit Burman and Mr. Jimeet Vipul Modi are not debarred from holding position of Director in any listed company by virtue of any Securities and Exchange Board of India (**SEBI**) Orders or any other authority.

The details, as prescribed under SEBI LODR read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith and marked as **Annexure - 1**.

Please take the above information on record.

Thanking You,

Yours faithfully,

For **Religare Enterprises Limited**

BABU RAO PRIYA

Babu Rao P.
Group General Counsel and Group Chief Compliance Officer

Annexure -1

Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No	Particulars	Details			
	Name of Person	**Dr. Anand Chand Burman (DIN: 00056216)**	**Mr. Aditya Chand Burman (DIN: 00042277)**	**Mr. Mohit Burman (DIN :00021963)**	**Mr. Jimeet Vipul Modi (DIN: 05285416)**
1	Reason for Change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment as Additional Director (designated as Non-Executive & Non-Independent Director, liable to retire by rotation)	Appointment as Additional Director (designated as Non- Executive & Non-Independent Director, not liable to retire by rotation)	Appointment as Additional Director (designated as Non-Executive & Non-Independent Director, liable to retire by rotation)	Appointment as Additional Director (designated as Non-Executive & Non-Independent Director, liable to retire by rotation)
2	Date of Appointment ~~/re-appointment /cessation (as applicable)~~ and term of appointment ~~/re-appointment~~	November 03, 2026 (date of receipt of approval of RBI) Term of appointment : 5 years from date of appointment	November 03, 2026 (date of receipt of approval of RBI) Term of appointment : 5 years from date of appointment	November 03, 2026 (date of receipt of approval of RBI) Term of appointment : 5 years from date of appointment	November 03, 2026 (date of receipt of approval of RBI) Term of appointment : 5 years from date of appointment
3	Brief Profile (in case of appointment)	Dr. Anand C. Burman is the Chairman Emeritus of Dabur lndia, one of India's leading consumer goods companies with presence in over 120 countries across the globe. Dr. Burman is a trained pharmacist and is widely recognized for his interests in Research & Development that has helped him earn over 40 patents against his name. Dr. Burman has particular interests in the areas of R&D in Pharmaceutical Sciences as well as Biotechnology and Technology issues. His education was both multidisciplinary and international. He completed his high school education from	A 6th generation member of the Burman family, Mr. Aditya Burman is a Director on the board of Dabur India Ltd, one of lndia's largest and most diverse consumer goods maker. A Chemistry Graduate from the University of Kansas (US), Aditya is part of the team providing strategic direction to Dabur's businesses spread across 120 countries. Aditya began his career as an intern at Dabur Pharma, a family-owned Oncology focused Pharmaceutical firm under his father Dr. Anand C.	Mr. Mohit Burman is the Chairman of Dabur India Limited, having its global presence in over 120 countries. He has to his credit acquisition of Balsara Hygiene and Home Care in 2005 enhancing Dabur's product portfolio and then Femcare Pharma Limited thereby expanding Dabur's skincare segment. He has been instrumental in expanding the group's financial services business into Asset Management and Life Insurance by setting up insurance Company AVIVA Life Insurance Company India Ltd.	Mr. Jimeet Modi is the Founder and Group CEO of SAMCO Group, which operates businesses across securities broking, wealth management, and asset management. He is also the Founder Director and Chairman of the Investment Committee, at SAMCO Asset Management. A qualified Chartered Accountant with an All India Rank 9 and a qualified Chartered Financial Analyst (CFA) from the CFA Institute, USA, Mr. Modi has been instrumental in driving the Group's strategic direction, technology led platforms, and quantitative investment frameworks. At SAMCO Asset Management, he

		St. Paul's School in Darjeeling, India and followed it with a B.Sc. in Chemistry from the University of Wisconsin and M. Sc. in Chemistry from the University of Kansas. His Doctorate was in the area of Pharmaceutical Chemistry from the University of Kansas in 1980. Further, Dr. Burman has more than 35 years of experience in the Non-Banking Financial Company (NBFC) sector. He is a Promoter and Director of Puran Associates Private Limited, NBFC, and has been associated with the company since October 1990. Over the years, he has been actively involved in guiding the company's financial and investment activities, including strategic decision-making, evaluation of investment opportunities, financial management, and ensuring compliance with applicable statutory and regulatory requirements. Dr. Burman is also a Promoter and Director of Milky Investment and Trading Company, NBFC and has been serving on its Board since April 2006. In this role, he has been involved in overseeing the company's investment and financial operations and participating in key policy and governance decisions. Dr. Burman is a member of the fifth	Burman. Fueled with grit and perseverance, Aditya worked towards expanding the company's footprint in the overseas markets and was soon in charge of its Sales and Marketing in Latin America. Under his stewardship, Dabur Pharma emerged as a leading research-driven pharmaceutical firm with a global presence. The company was subsequently sold to Fresenius Kaki in 2008. Further, Mr. Aditya Chand Burman, has around 20 years over all experience, out of which over 15 years rich experience is in the Non-Banking Financial Company (NBFC) sector through his association with various NBFC entities as a director. He had served as a Director in Milky Investment and Trading Company (MITC), registered with RBI as NBFC (ICC- Middle Layer) having registration number B-14. 03145 vide certificate of registration dated 07. 04. 2008, from September 2018 to June 2025. During this period, he was involved in participating in board-level	He has also played a pivotal role in establishing Universal Sompo General Insurance, a consortium with Allahabad Bank, Indian Overseas Bank, Karnataka Bank, and Sompo Japan. Further he has around 25 years of experience in the Non-Banking Financial Company (NBFC) sector. He has been associated with NBFC business activities since May 2001 and is serving as a Promoter and Director in NBFC entities. In his role as Promoter and Director, he has been involved in overseeing the investment and financial activities of the companies, participating in important business decisions, and guiding the overall financial and investment strategy. Through his continuous association with NBFC operations for nearly three decades, he has gained substantial experience in financial services, investment management, and the regulatory framework governing NBFCs. Further, he has led the Burman family's acquisition of a majority stake in Eveready Industries India Ltd., India's leading dry cell battery manufacturer and Punjab Tractors Limited which was later sold	oversees the development of model-driven investment strategies and portfolio frameworks. His work integrates principles of quantitative finance, risk management, and systematic investing to build disciplined, process-oriented investment solutions. In addition to his roles at SAMCO, he is also responsible for the management and oversight of the Modi Family Office, which focuses on long-term investments across public and private markets. He possesses a broad range of expertise spanning securities laws, contract laws, compliance, investments, financial analysis, accounting, taxation, management, and technology. His multidisciplinary experience enables him to bring a comprehensive perspective to corporate governance, financial strategy, and business operations.

		generation of Dabur group's founder family and took charge as chairman in 2007 after holding the post of vice-chairman and having been associated with the company in various other roles. His interests in R&D closely align with Dabur's focus on developing products that offer holistic wellness, and spearheaded Dabur's transformation from an Ayurvedic medicines maker to becoming India's 4th largest FMCG (Fast Moving Consumer Goods) player. He also serves as Director on the Board of Dabur Research Foundation, Dabur (UK) Limited, H&B Stores Limited, among others. He stepped down as the Chairman of Dabur India Ltd in 2019. Other than the Dabur Group Companies, he is a member of the Advisory Board of the Institute for Advancing Medical Innovation under the University of Kansas, USA. Dr. Burman is the recipient of numerous awards and honours, including the Ernst & Young Entrepreneur of the Year award in 2011.	discussions and overseeing the investment and financial activities of the MITC. He is also associated with Puran Associates Private Limited, (PAPL), a NBFC registered with RBI as NBFC (ICC-Middle layer), having registration number 14.00393 vide certificate of registration dated 1 1. 03. 1998 as a Director. Wherein they have gained exposure to the functioning of NBFCs, including investment activities, corporate governance, and compliance with applicable regulatory requirements. Born in January 1980, Aditya lives in Delhi and has also been supporting several charities in the Health Care and Health Awareness space. He has also been actively involved with agencies in supporting children suffering from Cancer.	to Mahindra & Mahindra after a successful turnaround. His Entrepreneurial Ventures include - H&B Stores Ltd. (NewU)- A beauty retail chain with over 90 stores across India, Burman Hospitality- brought Taco Bell to India, operating over 100 outlets. He is a seasoned entrepreneur and is associated in various capacities with different sports franchise teams in India. He is actively involved in various welfare activities aimed at improving the quality of life for underprivileged sections of society. He also supports elephant conservation initiatives through the Worldwide Fund for Nature-India.	
4	Disclosure of relationships between directors (in case of appointment of a Director)	Father of Mr. Aditya Chand Burman	Son of Dr. Anand Chand Burman	Nephew of Dr. Anand Chand Burman and Cousin Brother of Mr. Aditya Chand Burman	NIL